TOKEN2049
8.7.2022 10:45:13 CEST | Business Wire | Press release
TOKEN2049 , Asia’s premier crypto conference, has announced a new batch of title sponsors and speakers for its upcoming Singapore edition which will be running from 28 to 29 September. This year marks the conference’s Singapore debut, making for a thrilling week of activities as some of the world’s most pioneering projects gather at what’s set to be the crypto industry’s first major in-person event in Asia ahead of the Formula 1 Singapore Grand Prix 2022 race weekend.
In recognition of growing excitement around the event, TOKEN2049 Singapore’s roster of sponsors grew to 200 firms within the last three weeks. New additions to its line-up of title sponsors include next-generation crypto spot and derivatives trading exchange OKX ; leading hardware wallet manufacturer Ledger ; one of the world’s largest crypto exchanges Kucoin ; Hong Kong-based digital asset exchange AAX ; the world’s largest cryptocurrency derivatives copy trade platform Bitget ; and homegrown Singaporean crypto exchange Coinhako, which secured its major payment institution license earlier this year.
A notable addition to this year's Title Sponsor lineup is a leading South Korean game company WEMADE , best known as the creator of leading MMORPG series Legend of Mir which sees over 120 million players worldwide. WEMADE has been servicing blockchain games since 2020, and currently 14 titles are onboarded on its platform WEMIX , including MIR4, the number 1 play-to-earn MMORPG.
A WEMADE spokesperson said: “With the industry growing at unprecedented levels and the amount of innovation it’s channeling globally, TOKEN2049 and the important conversations that it will catalyse couldn’t have come at a better time.”
As the flagship event of Asia Crypto Week , the conference is expected to draw 3,000 attendees from across the world. This year’s impressive line-up includes Stani Kulechov, Founder and CEO of AAVE, the leading open-source and non-custodial liquidity protocol; Haseeb Kureshi, Managing Partner of Dragonfly Capital; and Eli Ben-Sasson, Co-Founder and President of Starkware and co-inventor of zkSTARK, the privacy-preserving cryptographic proof.
Panels and keynotes at the event are set to address a broad agenda — from the evolving regulatory landscape and institutional investment trends to the rise of the metaverse, Web3, and what this will ultimately mean for the industry as mainstream awareness intensifies.
The Singapore event is set to be the largest in TOKEN2049’s history amid the token economy’s huge potential to transform industries and communities around the world. As a testament to growing interest among broader mainstream audiences, McLaren Racing Formula One driver Daniel Ricciardo, the new brand ambassador for world-leading crypto trading app and web3 platform OKX, will also be speaking at the conference ahead of Sunday’s Singapore Grand Prix 2022 race, sharing his views on digital assets and the evolving nature of fan engagement.
Additional speakers at this year’s conference include Justin Sun, Founder of Tron, the open-source, Proof-of-Stake blockchain platform and Sandeep Nailwal, Co-Founder of Polygon, the decentralised Ethereum scaling platform.
Commenting on the 200-sponsor milestone, Raphael Strauch, Founder of TOKEN2049 said: “The numbers don’t lie, and this overwhelming interest and energy only bode well for the industry. I’m thrilled to see the conversations and solutions that will emerge from Singapore this September.”
As part of Asia Crypto Week, attendees can expect to attend a full line-up of side events, including Pantera Blockchain Summit Asia, Milken Institute Asia Summit, and Algorand AVM Singapore, with many more to be announced in the coming weeks.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005567/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom